Potential use of PEG-HbCO in severe anemia.

• DOI: 10.1200/jco.2015.33.15_suppl.e18086
• Publication Date: 2019-03-07T22:26:39Z
• Authors: Deven V. Parmar; Hemant K. Misra; John B. Berryman; Abraham Abuchowski
• Keywords: 03 medical and health sciences; 0302 clinical medicine; 3. Good health

e18086 Background: Patients who cannot receive blood transfusions in the presence of severe anemia can sustain significant morbidity and mortality. Religious beliefs hemolytic reactions are most common reasons for not transfusing a patient. Pegylated bovine carboxyhemoglobin (PEG-HbCO) has been used 5 such patients including patient developed reaction following stem cell transplantation. Methods: Five with hemoglobin (Hb) levels under 3.5 g/dL were treated repeated doses PEG-HbCO. Diagnoses included AML, reaction, acute chest syndrome sickle crisis. ranged age from 19 to 61. A unit PEG-HbCO consists 500 mL (40 mg/mL). Total 1 unit/day 2 4 days up 8 units given over 9 days. No adverse events associated reported. Results: Each investigator reported clinical improvements their administration PEG-HbCO, despite continuing low Hb levels. Patient well-being was also consistently improved. The number size allowed draws restricted; therefore analysis chemistries limited. One had increase cerebral oximetry another showed flow measured by TCD. extreme fatigue or neurological deficit each demonstrated increases responsiveness self-reported comfort within close temporal association treatment. undergone transplant immune anemia, resulting tachycardia. He received once-daily during which time his heart rate normalized be alert oriented. Conclusions: improved status these suggests that potential utility unable transfusions.